全文获取类型
收费全文 | 50646篇 |
免费 | 3862篇 |
国内免费 | 187篇 |
专业分类
耳鼻咽喉 | 449篇 |
儿科学 | 1559篇 |
妇产科学 | 1022篇 |
基础医学 | 6826篇 |
口腔科学 | 991篇 |
临床医学 | 4956篇 |
内科学 | 11200篇 |
皮肤病学 | 808篇 |
神经病学 | 4895篇 |
特种医学 | 1592篇 |
外国民族医学 | 2篇 |
外科学 | 7161篇 |
综合类 | 616篇 |
一般理论 | 38篇 |
预防医学 | 4108篇 |
眼科学 | 1056篇 |
药学 | 3746篇 |
1篇 | |
中国医学 | 68篇 |
肿瘤学 | 3601篇 |
出版年
2023年 | 283篇 |
2022年 | 178篇 |
2021年 | 931篇 |
2020年 | 670篇 |
2019年 | 944篇 |
2018年 | 1076篇 |
2017年 | 880篇 |
2016年 | 979篇 |
2015年 | 1090篇 |
2014年 | 1552篇 |
2013年 | 2151篇 |
2012年 | 3108篇 |
2011年 | 3355篇 |
2010年 | 1884篇 |
2009年 | 1751篇 |
2008年 | 2838篇 |
2007年 | 3176篇 |
2006年 | 2985篇 |
2005年 | 3067篇 |
2004年 | 2884篇 |
2003年 | 2664篇 |
2002年 | 2488篇 |
2001年 | 753篇 |
2000年 | 714篇 |
1999年 | 793篇 |
1998年 | 629篇 |
1997年 | 475篇 |
1996年 | 493篇 |
1995年 | 416篇 |
1994年 | 380篇 |
1993年 | 403篇 |
1992年 | 519篇 |
1991年 | 549篇 |
1990年 | 507篇 |
1989年 | 493篇 |
1988年 | 427篇 |
1987年 | 425篇 |
1986年 | 351篇 |
1985年 | 463篇 |
1984年 | 432篇 |
1983年 | 362篇 |
1982年 | 363篇 |
1981年 | 341篇 |
1980年 | 323篇 |
1979年 | 277篇 |
1978年 | 249篇 |
1977年 | 230篇 |
1976年 | 194篇 |
1974年 | 207篇 |
1973年 | 178篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Janitz Amanda E. Schraw Jeremy M. Xu Chao Lupo Philip J. 《Cancer causes & control : CCC》2022,33(3):483-488
Cancer Causes & Control - Congenital malformations are strong risk factors for childhood cancer. Our objective was to determine whether cancer survival differs by birth defect status among... 相似文献
2.
3.
Rupa Narayan MD Traci M. Blonquist MS Ashkan Emadi MD PhD Robert P. Hasserjian MD Meghan Burke BS Christopher Lescinskas BS Donna S. Neuberg ScD Andrew M. Brunner MD Gabriela Hobbs MD Hanno Hock MD PhD Steven L. McAfee MD Yi-Bin Chen MD Eyal Attar MD Timothy A. Graubert MD Christina Bertoli MSN Jenna A. Moran MSN Meghan K. Bergeron MSN Julia E. Foster MSN Aura Y. Ramos BSN Tina T. Som BSN Megan K. Vartanian BSN RN Jennifer L. Story LPN Kristin McGregor MS Molly Macrae BS Tanya Behnan BS Margaret C. Wey PhD Jessica Rae BSN Frederic I. Preffer PhD Patricia Lesho BA Vu H. Duong MD Mason L. Mann BA Karen K. Ballen MD Christine Connolly BS Philip C. Amrein MD Amir T. Fathi MD 《Cancer》2020,126(6):1264-1273
4.
5.
Philip S. Vendittelli Bassent Botros Howard S. Rosman Viren Govindaraju Anwar Zaitoun Tariq S. Marroush 《The American journal of the medical sciences》2019,357(4):333-337
Coronary embolism (CE) is an uncommon and unique cause of acute myocardial infarction. In this report, we review 216 cases of CE including 2 new cases from our institution. The mean patient age was 52.5 years and 62% of the patients were males. Chest pain was the most common presenting symptom followed by dyspnea, and the most commonly affected vessel was the left anterior descending artery. Leading etiologies of the embolus were atrial fibrillation, septic emboli, and iatrogenic causes. Treatment approaches varied with thrombus aspiration being used in 30% of cases. In-hospital mortality rate was 36% and 13% of the cases were complicated by cerebrovascular accident. CE is a unique pathology that leads to acute myocardial infarction. It portends a high mortality rate and requires a high level of suspicion as symptoms may be misleading. Further research is needed in order to improve recognition and management and to lower associated mortality. 相似文献
6.
Sarina A. Piha-Paul Do-Youn Oh Makoto Ueno David Malka Hyun Cheol Chung Adnan Nagrial Robin K. Kelley Willeke Ros Antoine Italiano Kazuhiko Nakagawa Hope S. Rugo Filippo de Braud Andrea Iolanda Varga Aaron Hansen Hui Wang Suba Krishnan Kevin G. Norwood Toshihiko Doi 《International journal of cancer. Journal international du cancer》2020,147(8):2190-2198
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. 相似文献
7.
8.
9.
10.
Christian Holm Hansen Shelley Lees Saidi Kapiga Janet Seeley Tony Barnett 《Global public health》2020,15(3):402-413
ABSTRACTMeasuring hope reliably and accurately remains an important research objective, not least in less prosperous settings where ‘holding on to hope’ may be critically important in the struggle against adverse life conditions. The State Hope Scale was designed for use in the US. Despite reported application in diverse cultures and using translations the scale has not been extensively validated outside US populations. This study contributes to a larger project exploring the measurement of hope and provides a critique of Snyder’s scale as used in a Tanzanian female population of 1021 urban microfinance participants. We evaluate the scale’s validity through assessment of the empirical distribution of scores, item response profiles, internal consistency and discriminatory ability. Participants mostly scored very high and many reached very near the maximum attainable score. Hardly any endorsed the negative half of the response scale. Several problems are discussed including poor discrimination and strong evidence of acquiescence response bias. We also found little association of the scale scores with hypothesised correlates of hope. Future improvements on the measurement of hope are recommended, especially in studies outside the narrow Western context in which the scale was devised. 相似文献